Navigation Links
Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway

d other biological pathways, as well as for the development of new therapeutic candidates such as nab-docetaxel (ABI-008) and the HSP90 inhibitor nab-17-AAG (ABI 010), among others.

About nab(TM) Technology Platform

Developed by Abraxis BioScience, nanoparticle albumin-bound (nab(TM)) tumor-targeting technology harnesses the unique natural properties of the human protein albumin, to transport and deliver therapeutic agents to the site of disease. The binding of albumin to the anticancer agent creates nanometer-sized particles, which are approximately 1/100th the size of a single red blood cell. These nab particles are readily incorporated into the body's own transport processes and are able to exploit the tumors' attraction to albumin, enabling the delivery of higher concentrations of the active drug to the target site. This may lead to an increase in the drug's antitumor effect and the potential for an effective response. In addition, nab technology offers the ability to improve a drug's solubility by avoiding the need for toxic chemicals, such as solvents, in the administration process, thus potentially improving safety through the elimination of solvent-related side effects.

Abraxis BioScience received approval from the U.S. Food and Drug Administration for ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease in 2005, its first product developed using the nab technology. Studies are ongoing to evaluate several other therapeutic candidates that employ the nab technology including nab-docetaxel (ABI-008), nab-rapamycin mTOR inhibitor (ABI 009), and nab-17AAG HSP90 inhibitor (ABI 010), among others.

About Abraxis BioScience, Inc.

Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
2. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
Post Your Comments:
(Date:10/8/2008)...clinical program to evaluate TAXUS(R) Element(TM) ...Stent, NATICK, Mass., Oct. 8 /PRNewswire-FirstCal...today announced that it has completed enrollment i...any,s third-generation,TAXUS(R) Element(TM) paclit...program has enrolled nearly 1,500 patients at 100 ...
(Date:10/7/2008)...DIEGO, Oct. 7 /- Prometheus Laborator...y announced findings from its,development of PROME...test,for irritable bowel syndrome (IBS). The findi...on of particular biomarkers in blood samples,betwe... these biomarkers,combined with a proprietary alg...
(Date:10/7/2008)...lts of FLEXX Trial Presented at the Osteoarthritis...ess, PARSIPPANY, N.J., Oct. 7 /- Fer...ts from the FLEXX Trial of Osteoarthritis of the,K...te), a highly pure,non-avian high molecular weight...is superior to intra-articular saline (IA-saline) ...
(Date:10/7/2008)... clinical study of adults, VYVANSE taken once-dail...in one week, PHILADELPHIA, Oct. 7 /PRNewswire-Fir...e global specialty biopharmaceutical company, toda...r issue of the Journal of,Clinical Psychiatry foun...ion Deficit Hyperactivity Disorder (ADHD) symptoms...
Breaking Medicine Technology:Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6Tongji Hires German Based Dr Petri Consulting GmbH for Langdong Project 24446 1Tongji Hires German Based Dr Petri Consulting GmbH for Langdong Project 24446 2Psychemedics Corporation Announces Second Quarter Results 24442 1Psychemedics Corporation Announces Second Quarter Results 24442 2Psychemedics Corporation Announces Second Quarter Results 24442 3Psychemedics Corporation Announces Second Quarter Results 24442 4Psychemedics Corporation Announces Second Quarter Results 24442 5Arcadia Radiology Medical Group Chooses AMICAS 6758 1Arcadia Radiology Medical Group Chooses AMICAS 6758 2Arcadia Radiology Medical Group Chooses AMICAS 6758 3Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation 2718 1Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation 2718 2Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation 2718 3Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation 2718 4
...pyridopyrazine-urea derivative compound series sho...e valuable for cancer,treatment , , QUBEC C... (TSX: AEZ; Nasdaq:,AEZS), a global, pure play b...erapy and oncology, today presented an abstract,...e derivatives,with high selectivity for PI3K inh...
...SINESS WIRE)--Apr 17, 2007 - Alnylam,Pharmaceutica...cs,company, announced today at the American Associ...ng that it will advance a,systemically delivered R...iver cancer and potentially other solid tumors as ...erapeutic that is,designed to target vascular endo...
Other Medicine Technology:terna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 2terna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 3terna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 4Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 2Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 3Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 4Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 5
(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
... nonsurgical image-guided treatment of kidney tumo...copic// technique in viable candidates. The resear...Radiology’s 32nd Annual Scientific Meeting. The ...ous cryoablation results in a slightly lower recur...
...s to help stroke survivors with the kind of comple...outside the box," according// to a University of I...participants' abilities were independent of any ch...improvements in complex mental abilities were not ...
...n are at a higher risk of perinatal mortality (dea...ies born to black or white women// , concludes a s... Health Organisation defines post-term pregnancy a...irst day of the last menstrual period. Post-term p...
...orld's largest maker of generic drugs and 19 other...ine medicines without federal approval. The Food ...s were part of an effort to halt the marketing of ...drugs. The goal is to get the unapproved drugs off...
Other Medicine News:Health News:Freezing Kidney Tumors Effective and Less Expensive Than Laparoscopy 2Health News:Antidepressants Improve Post-Stroke Mental Abilities 2Health News:Antidepressants Improve Post-Stroke Mental Abilities 3Health News:FDA Warns Migraine Medicine Makers 2
Adjustable tilt angle 0 to 20 Adjustable speed of 3-25 RPM Load capacity: 2.7 kg (6 lbs.) Ambient temperature range 4C to 65C Low voltage power is supplied by wall mount transformer
...al growth system, combines orbital shaking, oxygen...r bacterial growth. It is designed for easy integr...Extractor. The uniquely engineered HT-MegaGrowTM h...akers. Plate-holding cassettes allow for high plat...
Inquire
Inquire
Medicine Products: